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From purines to purinergic signalling: molecular functions and
human diseases
Zhao Huang1, Na Xie1, Peter Illes2,3, Francesco Di Virgilio4, Henning Ulrich2,5, Alexey Semyanov 6,7, Alexei Verkhratsky 2,7,8,
Beata Sperlagh9, Shu-Guang Yu2,10, Canhua Huang 1,11 and Yong Tang 2,10
Purines and their derivatives, most notably adenosine and ATP, are the key molecules controlling intracellular energy homoeostasis
and nucleotide synthesis. Besides, these purines support, as chemical messengers, purinergic transmission throughout tissues and
species. Purines act as endogenous ligands that bind to and activate plasmalemmal purinoceptors, which mediate extracellular
communication referred to as “purinergic signalling”. Purinergic signalling is cross-linked with other transmitter networks to
coordinate numerous aspects of cell behaviour such as proliferation, differentiation, migration, apoptosis and other physiological
processes critical for the proper function of organisms. Pathological deregulation of purinergic signalling contributes to various
diseases including neurodegeneration, rheumatic immune diseases, inflammation, and cancer. Particularly, gout is one of the most
prevalent purine-related disease caused by purine metabolism disorder and consequent hyperuricemia. Compelling evidence
indicates that purinoceptors are potential therapeutic targets, with specific purinergic agonists and antagonists demonstrating
prominent therapeutic potential. Furthermore, dietary and herbal interventions help to restore and balance purine metabolism,
thus addressing the importance of a healthy lifestyle in the prevention and relief of human disorders. Profound understanding of
molecular mechanisms of purinergic signalling provides new and exciting insights into the treatment of human diseases.
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INTRODUCTION
Purines and pyrimidines have long been recognised as funda-
mental elements of bioenergetics; while their role as chemical
transmitter was suggested 90 years ago, when in 1929, Albert
Szent-Gyorgyi and Alan Drury discovered that intravenous
injection of adenine into guinea pig disturbed cardiac rhythm,
indicating extracellular signalling function.1 Nearly two decades
later, Wilhelm Feldberg and Catherine Hebb reported that
adenosine triphosphate (ATP) stimulated the sympathetic gang-
lion in the cat.2 In 1959 Pamela Holton demonstrated that
antidromic stimulation of sensory nerves in the rabbit led to the
release of ATP.3 These findings suggested transmitter function
of purines in the nervous system. In 1972, Geoffrey Burnstock
proposed the purinergic neurotransmission hypothesis, which
described ATP as the non-adrenergic and non-cholinergic
neurotransmitter.4 This hypothesis failed to convince most
researchers at first, but has been gradually accepted after
molecular cloning of purinergic receptors which mediate signal
transduction in response to extracellular purines has been
accomplished. Purinergic receptors are commonly divided into
two classes based on agonist selectivity, namely P1 adenosine
receptors, and P2 nucleotide receptors (also known as ATP
receptors).5 These receptors are further sub-classified into several
subtypes, which are diffusely expressed in tissues and are
activated by different purine derivatives, thereby exerting specific
physiological functions.
Purinergic signalling interacts with other signal molecules to
form a complex network, regulating numerous cellular processes
including proliferation, differentiation, and death. For instance, ATP
activates metabotropic P2Y receptor to promote cell proliferation,
while activation of ionotropic P2X7 receptor arrests growth
through recruiting protein kinases p38/MAPK and SAPK/JNK.6
Given the key role of purines in fundamental metabolic processes,
and the involvement of purinergic transmission in the regulation of
fundamental physiological processes (such as blood coagulation7
and neurotransmission8), deregulation and malfunction of the
purine/purinergic system contributes to pathophysiology of
numerous diseases, including gout, diabetes, neurological disease,
osteoporosis and cancer (Fig. 1).
The best-known purine-related disease is gout, which results
from accumulation of urate crystals in joints. Deposition of
urate crystals is frequently associated with a purine-rich diet
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(i.e. seafood, animal offal, beer, etc.) or with renal insufficiency.
To date, several drugs targeting purine metabolism or purinergic
receptors have been developed (including tecadenoson, regrelor,
AF-219, JNJ-54175446, PPADS, A317491, etc.), and many such
drugs underwent successful trials or have been approved by the
US Food and Drug Administration (FDA) (for example regadeno-
son, istradefylline, dipyridamole, clopidogrel, prasugrel, cangrelor,
ticagrelor, etc.), further highlighting the importance of targeting
purinergic signalling in the clinic. In this review, we shall briefly
summarise main concepts and recent findings in purine biogen-
esis and metabolism, with a focus on the role of purinergic
signalling in cellular functions and several human diseases
including neurological disorders, rheumatic diseases and cancer.
We shall also discuss therapeutic approaches, with a focus on
traditional Chinese medicine (TCM) as a novel option for restoring
the balance of purine metabolism.
PURINOSOME AS THE FUNDAMENTAL UNIT TO REGULATE
PURINE METABOLISM
Purine metabolism affects a broad range of cellular processes,
including energy production and DNA/RNA synthesis. ATP is
hydrolysed to ADP and further to AMP, thereby meeting energy
demand and facilitating nucleotide assembly. Cyclic AMP (cAMP) is
the omnipresent second messenger controlling cellular physiologi-
cal responses, further highlighting the crucial role of purine
metabolism for the proper function of organisms. AMP can be
dephosphorylated into adenosine, which is shuttled across cell
membrane via equilibrative and concentrative nucleoside transpor-
ters (respectively, ENT and CNT)9. Adenosine translocation by ENT
equalises adenosine levels on both sides of cell membrane, while
CNT transports adenosine against a concentration gradient into the
cells to maintain a high adenosine level inside the cell.9 Adenosine
can be either recycled as AMP by phosphorylation, or converted
into uric acid as the final metabolite. On the other hand, AMP and
other purine nucleotides (i.e. inosine monophosphate (IMP),
xanthosine monophosphate (XMP), and guanosine monopho-
sphate (GMP)) can be converted into each other therefore
generating a cellular purine pool. There are two major pathways
maintaining this pool, namely the salvage cascade and de novo
synthesis (Fig. 2).10 The salvage pathway provides purine nucleotide
source by recycling degraded bases. In this cascade, AMP can be
generated from adenine, this reaction being catalysed by the
adenine phosphoribosyltransferase (APRT).11 Other purine nucleo-
tides such as IMP and GMP can be produced from hypoxanthine
and guanine, respectively; these processes are catalysed by
hypoxanthine-guanine phosphoribosyltransferase (HPRT).12 Cells
prefer salvage pathway over the de novo synthesis because of
lower energy costs. Besides, many cellular populations (for example
brain or bone marrow cells) lack the de novo purine synthesis
cascade, being thus highly dependent on the salvage pathway.13,14
When purines are in deficit, the energy intensive de novo pathway
is upregulated to meet increasing purine demand. Briefly, de novo
purine synthesis pathway begins with the consumption of phosphor-
ibosyl pyrophosphate (PRPP), and terminates with the production of
IMP. The entire de novo pathway is comprised of 10 highly regulated
reactions but only six enzymes are identified as direct participants,
because some of enzymes are multi-functional thus capable of
catalysing more than one reaction.15 For instance, trifunctional purine
biosynthetic protein adenosine-3 (trifGART) catalyses three steps,
namely conversion of 5-phosphoribosylamine (PRA) to glycinamide
ribonucleotide (GAR), of GAR to N-formylglycinamide ribonucleotide
(FGAR), and N-formylglycinamidine ribonucleotide (FGAM) to
aminoimidazole ribonucleotide (AIR) by its GAR synthetase (GARS),
Fig. 1 The causative role of purinergic signalling in human diseases. Purinoceptors, including P1, P2X and P2Y receptors, are diffusely
expressed in every human body part, such as the nervous system, circulatory system, respiratory system, immune system, urinary system and
others. Dysregulation of purinoceptors function leads to various diseases, including neurological, rheumatic, cardiovascular, cancer diseases
and so on
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GAR transformylase (GART), and AIR synthase (AIRS) domain,
respectively.16 Two other enzymes, the multifunctional protein
ADE2 (PAICS) and bifunctional purine biosynthesis protein PURH
(ATIC), catalyse two steps.17,18 Remaining three enzymes, namely
PRPP amidotransferase (PPAT), FGAM synthetase (FGAMS), and
adenylosuccinate lyase (ADSL) are identified as monofunctional
enzymes that catalyse only one reaction during the de novo
purine synthesis.19–21 In addition to higher energy cost, the de
novo pathway consumes more amino acids (i.e. glutamine,
glycine, aspartate) and additional metabolites (i.e. formate and
carbon dioxide) compared with the salvage pathway. This
metabolic shift resembles several hallmarks of cancer: rapidly
proliferating cancer cells require more amino acids (particularly
glutamine) and favour acidic tumour microenvironment, suggest-
ing a potential link between upregulated de novo purine
synthesis and carcinogenesis. This matter will be discussed in
following section.
To improve the utilisation of substrates and accelerate
metabolic flux, metabolic enzymes tend to form complexes
known as metabolon, frequently found in numerous metabolic
pathways, including glycolysis and tricarboxylic acid cycle (TCA
cycle). For example, the metabolon of glycolysis, termed a
glycosome, is a multi-enzyme structure containing a series of
glycosomal enzymes including hexokinase (HK), phosphofructoki-
nase (PFK), alanine transferase (ALT) and many others.22 Similar
metabolon also exists in the de novo purine synthesis pathway.
Using fluorescence imaging technique, all six enzymes in the de
novo pathway have been found to interact with each other to
form a metabolon, defined as “purinosome”.23 In response to
limited purine supplement, the purinosome promotes production
of purines to meet nutrient demand. In HPRT1-mutated cells, that
lack purine salvage capability, purinosome assembly undergo a
25% increase.24 In purinosome-rich cells, a 3-fold increase in IMP
level was observed compared with normal cells.25 Binding
efficiencies among six enzymes within purinosome are not
comparable. The three enzymes PPAT, trifGART and FGAMS bind
each other with a strong interaction thus forming the core of
purinosome. In contrast the interaction of PAICS, ADSL and ATIC is
relatively weak making them peripheral components.26 In addition
to six de novo synthesis enzymes, some other purine-related
enzymes are included in the purinosome, indicating that the
purinosome is not only involved in the de novo purine synthesis,
but contributes to other purine metabolic pathways. One of these
additional components is adenylsuccinate synthase (ADSS), which
catalyses the biogenesis of AMP from IMP.25 The inosine
monophosphate dehydrogenase (IMPDH) that catalyses conver-
sion of IMP to XMP, is also a member of purinosome.25 Several
non-enzyme proteins that seem to be irrelevant for purine
metabolism are also included in purinosome, such as the
chaperones HSP70 and HSP90.27 The formation of purinosome is
highly dynamic, for the depletion of purines in the medium
promotes the assembly of purinosome, while a purine-rich
medium leads to disassociation of the enzyme complex.23 These
observations suggest that under purine-rich or depleted condi-
tions, cells are capable to perceive extracellular purine level and
regulate de novo purine synthesis by dynamically controlling the
assembly and turnover of purinosome.
Although the dynamic regulation of purinosome formation and
disassembly has been described long time ago, the underlying
molecular cascades remain largely undefined. The finding that key
Fig. 2 De novo and salvage pathway for purine synthesis. PRPP generated from glycolysis and pentose phosphate pathway (green) serves as
substrate for de novo purine synthesis (blue background). After 10-step reaction catalysed by six enzymes with different functional domains,
IMP is produced as the end of de novo pathway. Salvage pathway (orange background) is mainly catalysed by two enzymes, namely HPRT and
APRT. In this pathway, PRPP is also needed, and several nucleosides serve as co-substrates for the production of nucleotides. The final
metabolite uric acid is further oxidised by uricase (grey), which is expressed in most organisms but lost in humans and a part of primates
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components of purinosome undergo phosphorylation implies that
certain kinase signalling pathways are critical to this process. A high-
throughput study targeting human kinome revealed that the
mammalian target of rapamycin (mTOR) facilitates the colocalisation
of purinosome with mitochondria, which are required for optimal
function of the purinosome itself.28 Given the high energy demand
of the de novo purine synthesis, the spatial colocalisation with
mitochondria provides high concentrations of ATP to support a
series of purinosome-associated enzymatic reactions. Purines thus
generated can be immediately utilised for the production of ATP. It
is not surprising that microtubule participates in this spatial
organisation of purinosome, for cytoskeleton largely affects the
formation and disassociation of protein complexes and regulates
their subcellular localisation. This hypothesis is supported by the
finding that the purinosome is co-localised with microtubule, and
disruption of the microtubule network impedes de novo purine
synthesis.29 Microtubule depolymerisation by nocodazole treatment
abrogates the co-localisation between purinosome and mitochon-
dria, indicating that microtubule-directed transport contributes to
purinosome–mitochondria co-localisation.30 The mTOR indeed
regulates microtubule-dependent protein transport.31 This evidence
suggests that mTOR–microtubule–purinosome–mitochondria axis
plays a central role in the complex formation and spatial regulation
of purinosome. Apart from mTOR, other kinases may also be
involved in this process. For instance, inhibition of casein kinase II
(CK2) has been shown to induce a disassociation of purinosome
clusters and affect de novo purine biosynthesis in HeLa cells.32
Moreover, 3-phosphoinositide-dependent protein kinase 1 (PDK1)
has been found to regulate the core assembly of purinosome
through its cytoplasmic activity, but independent of its
membrane-bound activity.33 It is worth mentioning that G-protein
coupled receptor (GPCR) signalling, which regulates a great number
of kinases such as PI3K, PKA, Akt, PKC, facilitates purinosome
assembly, suggesting that additional kinases are probably involved.34
ABERRANT PURINE METABOLISM CAUSES HYPERURICEMIA
AND GOUT
Gout, the archetypal purine-related disease has an estimated
incidence between 2.7% and 6.7% that is positively correlated with
a western lifestyle.35 In mainland China, the incidence of gout was
0.9% in 2000–2005 but increased to 1.4% in 2011–2014, which
reflects a rapid metamorphosis in the life style.36 Hyperuricemia is
the major risk factor for gout, as it is caused by deposition of the
monosodium form of urate (MSU) in the joints.37 Urate is the final
metabolite of purine metabolism, and therefore dysregulation of
purine catabolism contributes to gout (Fig. 3). There are multiple
causes accounting for hyperuricemia and the deposition of MSU.
Firstly, a purine-rich diet induces urate overproduction. Purine-rich
foods include seafood, meat, animal offal, and alcoholic beverages,
which all are associated with prosperous living condition. Alcohol
and certain purine-free drinks, including fructose-containing bev-
erage are also risk factors due to their ability to accelerate nucleotide
breakdown, therefore increasing urate production.38–40 Conversion
of fructose into fructose-1-phosphate requires consumption of ATP,
leading to increased AMP level. Accumulated AMP enters into purine
catabolic pathway to produce uric acid.41 Similarly, alcohol
metabolism in liver consumes a large amount of ATP to generate
AMP and thereby contributes to hyperuricemia.42 Secondly, loss of
uricase (also known as urate oxidase) also probably leads to MSU
Fig. 3 Dysregulated purine metabolism contributes to gout and pain. Purine-rich diet and several beverages, including meat, seafood, animal
offal, beer and fructose containing drinks, lead to high level of uric acid in vessel, termed hyperuricemia. Deposition of urate in joint induces
local inflammation. In this process, adenosine (ADO) and ATP function as neurotransmitters to activate P1 and P2 purinergic receptors,
respectively. This purinergic neurotransmission induces intense pain in gout patients
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deposition. In most organisms from bacteria to mammals, urate is
oxidised by uricase to form soluble allantoin to avoid deposition.
However, in humans and parting in some primates, this enzyme is
lost.43 Given that urate also functions as an antioxidant, loss of
uricase provides substantial advantages for humans against
oxidative stress-related diseases such as neurodegeneration and
cancer.44 From this perspective, potential side effects should be
considered while treating gout with recombinant uricase.45 Thirdly,
compromised excretion by kidneys and gut largely contributes to
hyperuricemia. Approximately two-thirds of uric acid is excreted by
kidneys, while gastrointestinal tract is responsible for the remaining
one-third.46 This explains why the elders, in whom renal and
gastrointestinal function is impaired, are more likely to have gout.
Mechanistic studies revealed that transporter-mediated urate
traffic is closely associated with hyperuricemia induced by renal
and gastrointestinal underexcretion. Serum urate level is mainly
determined by four transporters, namely URAT1 (encoded by gene
SLC22A12), GLUT9 (SLC2A9), NPT1 (SLC17A1) and ABCG2.47 In
kidney, proximal tubular cells express all four transporters to
balance serum urate. URAT1 localises at the apical side of proximal
tubular cells, importing urate from renal tubule into lining cells.48
A fraction of cellular urate is then transported to blood via GLUT9,
which localises at the basolateral side of proximal tubular cells.49
Alternatively, cellular urate can also be excreted into renal tubule
via ABCG2 and NPT1, both of which localise at the apical side of
proximal tubular cells.50,51 ABCG2 has been also found on the
apical side of enterocyte, excreting urate into intestinal lumen.52
Clinical data suggest that a number of single-nucleotide
polymorphisms (SNPs) exist in the encoding genes, leading to
gain-of-function or loss-of-function in these four transporters.
Thus, gain-of-function SNP in URAT1 and GLUT9, as well as loss-of-
function SNP in ABCG2 and NPT1 increase the risk of gout. In
contrast, loss-of-function mutations of the former two genes or
gain-of-function mutation in the latter two may reduce the risk of
gout. For instance, R90H and W258X non-functional mutations of
URAT1 have been shown to decrease the risk of hyperuricemia.53
In addition, loss-of-function mutations of GLUT9 (i.e. C210F,
N333S, etc.) are associated with lower serum urate.54 Introduction
of the Q141K mutation (linked to a common SNP rs2231142) to
ABCG2 halved urate transport hence reducing its contribution to
development of gout.55 The gain-of-function mutation, I269T on
NPT1, facilitates urate clearance and decreases the risk of gout.51
Moreover, these critical transporters might be regulated by
genetic variants present in other genes. A recent genome-wide
association study (GWAS) identified 183 loci associated with
serum urate levels. Among these SNPs, the T139I on HNF4A
upregulates its ability to activate ABCG2 promoter, leading to
ABCG2 overexpression, which is negatively associated with serum
urate level.56 Such genetic modifications are much more
complicated, thus again highlighting the importance of a
balanced diet in the prevention and relieve of hyperuricemia.
The definition of hyperuricemia is based on the laboratory data
showing that urate begins to crystallise at a concentration of
0.41mmol/L.57 Those crystals, known as MSU depositions, can be
detected by microscopy and used as the gold standard for the
diagnosis of gout. The preferred sites of MSU deposition are joints,
including first metatarsophalangeal joint, ankle, knee, and organs
such as the kidney. Deposition of MSU leads to acute inflammation
and intense pain known as gout flare. Inflammation at affected joints
is largely induced by the recruitment of immune cells (i.e. infiltrating
macrophages, neutrophils, etc.) and accumulation of pro-
inflammatory cytokines (i.e. IL-1β, IL-6, etc.).58 Mechanistic studies
demonstrated that MSU crystals bind to membranes of macrophages
instigating potassium efflux and the activation of NLRP3 inflamma-
some.59 This allows autocleavage of pro-caspase-1 into its mature
form, which in turn processes pro-IL-1β to bioactive IL-1β. After
activation of macrophages, neutrophils are recruited to inflammatory
sites where they generate reactive oxygen species (ROS) and
pro-inflammatory cytokines, thereby enhancing gout flare.60 Gout
flare is a self-limiting process that resolves within about 10 days,
probably because of build-up of anti-inflammatory cytokines
including IL-10, TGFβ1 and IL-37.61,62 Neutrophils also play a role in
the resolution of gout flare. Mounting a defensive response,
neutrophils release their contents including chromosomal DNA and
proteins to form neutrophil extracellular traps (NETs), which
sequester pro-inflammatory cytokines such as IL-6 and TNF.63
Despite a transient relief of gout flare, MSU crystals fail to be
removed from affected joint sites. Instead, MSU crystals bind to NETs,
and aggregate in the connective tissue to form subcutaneous
nodules termed tophi, the presence of which indicates a late stage of
gout known as tophaceous gout.64 It may take decades to develop
tophaceous gout after the first attack of gout flare, and a urate-
lowering therapy is effective for arresting this severe disease.65
Tophaceous gout is frequently accompanied by bone damage. It has
been shown that MSU crystals deposit on the synovial surface,
causing a cortical break then progresses into bone erosion.66
Mechanistic studies demonstrated that MSU crystals reduce the
viability of osteoblasts but enhance the development of osteoclast,
leading to a resorptive state and subsequent bone loss.67,68 In line
with it, a large-scale epidemiologic study revealed a 20% increased
risk of osteoporosis in patients with gout compared with gout-free
controls.69
Numerous studies indicate that lifelong urate-lowering therapy
is the key for the management of gout. Based on metabolic
pathways of urate production and turnover, several pharmacolo-
gical strategies have been developed to achieve these blood urate
targets. Uric acid is generated through the oxidation of xanthine
by xanthine oxidase, therefore two inhibitors of xanthine oxidase,
allopurinol and febuxostat, are currently used as the first-line
defence agents.70 Allopurinol is a hypoxanthine analogue that
binds and inhibits xanthine oxidase.71 In addition to decreasing
uric acid production, inhibition of xanthine oxidase also results in
an accumulation of hypoxanthine, which enters purine salvage
pathway. This effect probably induces feedback inhibition of PPAT,
the first enzyme of purine de novo synthesis to further block urate
production.72 In clinical practices, dose escalation of allopurinol
showed a better urate-lowering effect without increasing adverse
responses.73 The safety of this drug is closely related to individual
genetic and renal function. A rare but severe side effect,
allopurinol hypersensitivity syndrome, may occur in patients
carrying the HLA-B*5801 allele.74 Allopurinol usage can likely be
a risk factor for renal disease.75 Allopurinol taken orally, rapidly
metabolises into oxipurinol, which is slowly excreted by kidney.76
Given that gout patients frequently suffer from kidney impair-
ment, administration of allopurinol probably increases the renal
burden. This finding however, is controversial. A large-scale study
indicated that allopurinol decreases the risk of chronic kidney
diseases, suggesting the impact of allopurinol on kidney needs to
be further examined.77 In contrast, another drug febuxostat is
metabolised by liver and therefore it is not likely to impair kidney
function. In hyperuricemic patients with chronic kidney diseases,
febuxostat has been shown to be a better choice than allopurinol
for delaying renal impairment.78 Febuxostat however, may cause
acute liver injury.79 Moreover, treatment with febuxostat led to a
higher mortality in gout patients with cardiovascular diseases,
compared with allopurinol.80 Taken together, these observations
suggest that both xanthine oxidase inhibitors hold curative
effectiveness although potential side effects should not be
overlooked. In addition to severity, therapeutic options depend
on a variety of factors including individual genetic variation and
the condition of kidney, liver as well as cardiovascular system.35,81
PURINOCEPTORS IN PATHOPHYSIOLOGY
Purines exert essential pathophysiological effects by acting at
purinergic receptors, the concept of which was introduced by
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Geoffrey Burnstock.82 Purinergic receptors are divided into two
subfamilies known as P1 and P2 receptors. P1 receptors are G-
protein-coupled receptors that recognise adenosine as endogen-
ous ligand and are involved in a large number of physiological
responses, such as modulation of heart rhythm.83 In early 1990s,
four members of P1 receptor family A1, A2A, A2B and A3, were
cloned and characterised.84 These P1 receptor subtypes exhibit
different affinity to adenosine, distinct pharmacology and tissue-
specific expression patterns.85 Briefly, A1, A2A and A3 receptors
have high affinity, hence they are activated by physiological level
(nM) of extracellular adenosine. On the contrary, the activation of
A2B requires much higher adenosine concentration (μM), which
seems to be associated with pathological conditions such as
hypoxia.84,86 A1 receptors are mostly localised in the nervous
system, while the remaining three subtypes are diffusely
expressed in a broad range of tissues including nervous system,
spleen, colon, testis and others.87 Functionally, adenosine
receptors are coupled with different G proteins, modulating the
activity of adenylate cyclase (AC) in a positive or negative manner,
thus affecting cytoplasmic cAMP. Both A1 and A3 receptors couple
with Gi protein, hence their activation suppresses AC with
subsequent decrease in cAMP level. In contrast, A2A and A2B are
linked to Gs protein which stimulates AC.
85 Extracellular adenosine
activates A1 and A2 receptors of cardiac myocytes and cardiac
fibroblasts, respectively, leading to a downregulated cAMP
production in cardiac myocytes but an increase of cAMP level in
cardiac fibroblasts, thereby preventing myocardial hypertrophy
and fibrosis.88 Apart of AC, adenosine receptors regulate other
effectors such as phospholipase C (PLC) and mitogen-activated
protein kinase (MAPK).89,90 PLC controls the production of diacyl
glycerol (DAG), an endogenous activator of protein kinase C, and
inositol 1,4,5-trisphosphate (InsP3) that triggers Ca
2+ release from
endoplasmic reticulum (ER) Ca2+ store. Different adenosine
receptors can form functional heteromeric complexes. For
example, A1–A2A complex binds to both Gi and Gs proteins thus
triggering opposite cAMP signals. The outcome of this bidirec-
tional complex depends on the adenosine concentration. Low
adenosine concentrations preferentially activate the A1 subunit
thus suppressing AC activity. When adenosine is high, A2A
component is activated causing increase in cAMP production.91,92
Although the pathophysiological function of P1 receptors is
extremely complex, adenosine is generally considered a “protec-
tive” signal against stress conditions, because adenosine
decreases energy intense activities and enhances nutrient
support.93 This property makes P1 receptors attractive targets
for treatments of cardiovascular and other diseases.94
The P2 nucleotide receptor family is divided into two
subfamilies, P2X (ATP-gated ion channels) and P2Y (metabotropic
GPCRs).95 P2Y receptors are activated by several nucleotides
including ATP, UTP, ADP and UDP, whereas P2X are only activated
by ATP. In 1993, the first two P2Y receptors were cloned, and the
first two P2X receptors followed one year later.96–99 To date, seven
P2X (P2X1–7) and eight P2Y receptor members (P2Y1, P2Y2, P2Y4,
P2Y6, P2Y11, P2Y12, P2Y13 and P2Y14) are recognised. By analogy to
P1 adenosine receptors, P2Y receptors couple to specific G
proteins thus differentially regulating downstream effectors
including AC and PLC. P2Y1, P2Y2, P2Y4 and P2Y6 receptors couple
to Gq protein, which activates PLC β to induce Ca
2+ release from
ER. In contrast, P2Y12, P2Y13 and P2Y14 couple to Gi protein, which
inhibits AC to decrease cellular cAMP. P2Y11 receptors are linked
to both Gq and Gs and their activation triggers cAMP and Ca
2+
signalling.100 As mentioned above, P2Y receptors recognise not
only ATP, but also other nucleotides as endogenous ligands, albeit
with different efficacies. For instance, ADP is a more effective
agonist at P2Y1 than ATP
101. In contrast, P2Y2 has similar affinity
for ATP and UTP, but is insensitive ER to ADP.102 Other P2Y
receptors, including P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and P2Y14,
prefer UTP, UDP, ATP, ADP, ADP and UDP-glucose, respectively.103
Additional chemical groups affect the potency of nucleotides at
P2Y receptors. At P2Y12, 2-methylthio-ADP (2-MeSADP) is more
potent than ADP, but adenosine-5′-O-(2-thiodiphosphate) (ADPβS)
is less potent.104 Protein orthologs in different species have
distinct preference and affinity for agonists. For example, at
human P2Y4 UTP is the most potent agonist, whereas at rat P2Y4
UTP and ATP are equipotent.105,106
P2X receptors are archetypal ATP-gated cation channels,107 with
ATP being the only known physiological agonist.108 The family of
P2X receptors comprises seven members (P2X1–7) which assemble
as homo- or heterotrimeric complexes. Among homotrimeric P2X
receptors, P2X1 shows the highest affinity for ATP being activated
at ATP concentrations <1 μM.109 The least sensitive member is the
P2X7 receptor which requires ATP concentrations in hundred
micromolar range for activation.110 High ATP sensitivity is
frequently accompanied with a rapid desensitisation, whereas
less sensitive subtypes might show persistent activation.108
According to ATP sensitivity and desensitisation time, homo-
trimeric P2X receptors are roughly classified into four subtypes.
The first type includes P2X1 and P2X3 receptors, which are most
sensitive to ATP and are rapidly desensitising. The second type
includes P2X2 and P2X5 receptors with a lower ATP sensitivity and
slower desensitisation. The P2X4 receptor belongs to a third type
having similar ATP sensitivity, but prolonged desensitisation
compared with the second type. The last type, represented by
P2X7 receptors, shows the lowest ATP sensitivity and basically no
desensitisation.111 The remaining member, the P2X6 receptor is
not classified into these groups because it lacks the ability to form
homotrimeric receptors.112
Similar to P2Y receptors, P2X receptors can be activated by ATP
analogues with different potencies. For activation of P2X1, P2X2,
P2X3 and P2X5, 2-MeSATP is equipotent with ATP. On the
contrary, 2-MeSATP is 10-fold less potent than ATP at P2X4
receptors, and 100-fold less potent than ATP at P2X7 receptors.
113
Composition of heterotrimeric channels may be rather compli-
cated. For example, P2X1/2 heterotrimeric receptor is made of
single P2X1 and two P2X2 subunits, whereas P2X2/3 receptor is
assembled from a single P2X2 and two P2X3 subunits.
114,115 The
P2X2/4/6 receptor contains three different subunits, which is rarely
observed for other P2X heterotrimers.116 This diversity of
assembly confers to P2X receptors a large repertoire of
physiological functions in different tissues.
Several P2 receptor agonists and antagonists have been
developed for the treatment of human diseases. The examples
are many; for instance, thienotetrahydropyridines that irreversibly
inactivate P2Y12 receptors are used as antithrombotic drugs.
117
The P2X3 receptor antagonist, AF-219 is under phase 2 clinic trail
for treating refractory chronic cough.118 The rationale underlying
these successful trails is that ATP generally acts as a proin-
flammatory signal, hence antagonists targeting P2 receptors may
help restrain inflammation. To the contrary, adenosine restricts the
inflammatory response, suggesting a therapeutic potential for P1
receptor agonists as anti-inflammatory drugs. Neladenoson, an A1
receptor agonist demonstrated positive results in the treatment of
heart failure.119 Another promising application for modulators of
purinergic signalling is a cancer therapy. Firstly, an inflammatory
microenvironment has long been regarded as a hallmark of
cancer.120 Secondly, tumour microenvironment is rich in ATP and
adenosine.121 Thirdly, a variety of purinergic receptors are
expressed in a wide range of tumour types.122 Moreover, ATP
and adenosine are critical for the energy metabolism of cancer
cells. Following scattered reports on the anti-cancer activity of
some purinergic agonists,123,124 several clinical trials have been
initiated to test the effectiveness of A2A antagonists, alone or in
combination with other established chemotherapeutic or immune
check-point blockers, in cancer therapy.125,126 In addition, the
discovery that the tumour microenvironment is rich in
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extracellular ATP127 has fuelled trials designed to exploit this
peculiar trait of tumours to confer selectivity to anticancer
drugs.128
PURINERGIC NEUROTRANSMISSION IN NEURODEVELOPMENT
AND THE PATHOGENESIS OF BRAIN DISEASES
It is now well established that ATP is a bona fide neurotransmitter,
contributing to the numerous functions of the nervous system
(Fig. 4).129 In neuronal terminals ATP is accumulated within
synaptic vesicles by vesicular nucleotide transporter VNUT/
SLC17A9.130 This transporter is widely expressed in the brain,
and is central for ATP concentration (>100 μM) in the lumen of
vesicles. Genetic deletion of VNUT suppresses ATP exocytosis in
PC12 chromaffin cell line, suggesting VNUT-mediated vesicular
storage of ATP is critical purinergic transmission.130 The ATP-rich
vesicles are secreted by exocytosis in a Ca2+ regulated manner;
treatment with Ca2+ chelators or exocytosis inhibitors abolishes
ATP release.131 This Ca2+-dependent exocytosis of ATP vesicles
can be directly visualised by live cell imaging.132 Several non-
vesicular ATP release mechanisms were also reported, including
large transmembrane channels represented by P2X7 receptors,
connexins or pannexins.133,134 ATP is frequently released in
combination with other transmitters. For instance, ATP has been
found to be coreleased with noradrenaline (NA) and acetylcholine
(ACh) in cortical synaptosomes135 and with glutamate in cortical
slices134 ATP operating as a sole neurotransmitter has been found
only in medial habenula.136
A fraction of released ATP activates P2 receptors in an
autocrine/paracrine fashion. Remaining extracellular ATP under-
goes hydrolysis to yield diphosphate nucleotides which activate
several P2Y receptors, or is further broken down to produce
adenosine thus activating P1 receptors. In this way, ATP or its
metabolites stimulate para- or autocrinally purinergic receptors on
the post- or presynaptic membrane, respectively. For example,
ATP activates P2X3 and P2X2/3 receptors on the presynaptic
membrane of spinal cord neurones, therefore regulating bladder
micturition reflex.137 On the postsynaptic side, ATP-induced
current can be evoked by the activation of P2X2, P2X4, P2X6
ionotropic as well as P2Y metabotropic receptors.138 As a
cotransmitter, ATP may regulate other neurotransmission path-
ways. It has been shown that P2X2 activation induces internalisa-
tion of glutamate receptor (AMPAR) on postsynaptic side, leading
to a decrease of synaptic current in hippocampal neurones.139
Another glutamate receptor, N-methyl-D-aspartate receptor
(NMDAR), is also regulated by P2X receptors.140 In addition to
the postsynaptic expression of glutamate receptors, the release of
glutamate on the presynaptic membrane is regulated by both
excitatory P2 receptors, including P2X1, P2X2/3, P2X3, and
inhibitory receptors P2Y1, P2Y2 and P2Y4.
141 The bulk of
extracellular ATP is readily degraded by ectonucleotidases to
adenosine, which activates P1 receptors and generally functions
as an inhibitory signal. Among P1 receptors, A1 and A2A are two
major subtypes responsible for purinergic signalling in the
brain.142 For instance, activation of A1 by adenosine results in a
decrease of glutamate release and NMDAR expression on the
Fig. 4 Purinoceptors mediates neurotransmission in nervus system. In presynaptic terminal, ATP is enriched in vesicles by transporter VNUT
and then released in a Ca2+-dependent manner, or exported by other channels such as Panx1 independent of Ca2+. On one hand,
extracellular ATP and its degradation product adenosine in turn activate purinoceptors in presynaptic terminal. This effect may regulate the
release of other transmitters such as glutamate. On the other hand, extracellular ATP and adenosine can interact with postsynaptic
purinoceptors, thereby regulating the excitability of neural cells. This event might also lead to the internalisation of AMPAR and NMDAR on
postsynaptic membrane, leading to a decrease of glutamate-induced current. VNUT vesicular nucleotide transporter, Panx1 pannexin 1, AD
adenosine, AMPAR AMPA receptor, NMDAR N-methyl-D-aspartate receptor
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presynaptic and postsynaptic membrane, respectively.143–145
Similarly, adenosine-mediated A2A activation has been also found
to inhibit glutamate release and NMDAR expression.146,147 Other
details of purinergic neurotransmission have been extensively
reviewed elsewhere.148
Purinergic signalling modulates embryonic neurodevelopment
as well as neuroregeneration. Inner cell mass of blastocyst gives
rise to the neural tube, in which progenitor cells differentiate to
form peripheral and central nervous system, and these processes
are largely regulated by purines and purinergic receptors.149 On
rat embryonic day 11 (E11), P2X3 receptors are expressed in the
hindbrain neural tube to support the development of autonomic
nervous system.150 Genetic ablation of P2X3 receptors in mice
eliminates inward currents in vagal sensory neurons and impairs
their ability to sense gastric distension.151 Transcriptomics of the
embryonic rat brain showed that P2Y1 receptors are hardly
observed on E14 but are strongly expressed on E18, whereas P2Y4
maintains a comparable expression level throughout these
days.152 In addition to this temporal regulation, expression of
purinoceptors is region-dependent. On E9, P2X5 receptors are
expressed throughout the spinal cord. However, 2 days later these
receptors are detected only in the ventral horn, which is relevant
to the development of motor fibres.153 Another purinergic
receptor, P2Y2, is specifically expressed in the spinal motor nerves
but not in the brain at E12.152 This purinergic receptor is co-
localised with tyrosine receptor kinase A (TrkA) during neuronal
differentiation, knockout of the latter abrogates the axonal growth
of sciatic nerve in response to the stimulation of ATPγS.154 As to
the P1 adenosine receptors, administration of P1 antagonists to
pregnant mice delays migration of certain neurones, thus
affecting brain maturation and leading to an impaired memory
in foetal mice.155 Mechanistically, purinergic transmission mod-
ulates proliferation, differentiation, and migration of neural stem
cells (NSCs) and neural progenitor cells (NPCs), contributing to
neurodevelopment in foetal nervous system and neuroregenera-
tion in the adult brain.156 Neurogenesis in the adult brain occurs in
two niches, in subgranular zone (SGZ) in hippocampal dentate
gyrus and subventricular zone (SVZ) in the lateral ventricle.157 The
radial stem astrocytes which populate these regions symmetrically
divide into daughter NSCs with self-renewal capabilities and
asymmetrically into NPCs with highly proliferative properties;
these latter give rise to neuroblasts. Several purinergic receptors
regulate adult neurogenesis. For instance, the expression of P2X7
receptors has been detected in both embryonic SGZ/SVZ and in
the adult hippocampus.158 In embryonic NSCs, activation of P2X7
receptors accelerates cell proliferation and inhibits differentia-
tion.159 In the adult hippocampus, to the contrary, P2X7 receptors
suppress the growth of NPCs and promote the differentiation into
neurones and astrocytes.160 This effect may contribute to the
damage repair in the adult brain by restricting inappropriate cell
proliferation and facilitating neuronal production. Metabotropic
P2Y1 receptors, stimulate proliferation and migration of neural
progenitors, but do not affect their differentiation.161 In a P2Y1
receptor knockout mouse model, the downregulation of P2Y1
receptors was a prerequisite for the production of neuroprotective
astrocytes during brain repair.162 In the presence of neurotrophins,
ATPγS-mediated TrkA phosphorylation leads to neuronal differ-
entiation in wild-type, but not in P2Y2 receptor-null mice,
indicating that P2Y2 receptor is required for neurotrophin-
induced regeneration.154 Elimination of unnecessary neural cells
is a vital process during neurodevelopment, in which several
purinoceptors including P2X4, P2X7, P2Y2 and P2Y6 receptors are
involved.163–166 Modulation of neuronal apoptosis is largely
attributed to excessive Ca2+ release from the ER, the process
controlled by PLC/InsP3/InsP3 receptor axis downstream of
purinoceptors.167
Aberrant purinergic transmission in the brain contributes to the
pathogenesis of neurodegenerative disorders (i.e. Alzheimer’s
disease, Parkinson’s disease, Huntington’s diseases, etc.) and
neuropsychiatric diseases (i.e. depression, anxiety, addiction, etc.)
(Table 1).168–171 Alzheimer’s disease (AD) is manifested by impaired
cognition and memory and it is currently incurable. Deposition of
β-amyloid aggregates is generally considered to be the primary
cause of neuronal loss and a decreased level of ACh in brain,
whereas other factors such as hyperphosphorylation of tau protein
and disturbed metabolism of metal ion are also proposed.
Numerous studies focusing on purinergic signalling provide another
explanation for AD. As mentioned above, two P1 receptors A1 and
A2A are mostly responsible for the effects of adenosine in brain.
Generally, the roles of A1 and A2A in AD progression seem to be
context-dependent, with both protective and deleterious conse-
quences have been observed in the treatment of P1 agonists or
antagonists. In AD patients, the expression of A1 receptors is
downregulated in the hippocampus, whereas the expression of A2A
is upregulated in the periphery.172,173 Mechanistic study revealed
that A1 receptors are co-localised with Aβ aggregates, and activation
of A1 receptors leads to phosphorylation of PKC and ERK, which
stimulates the production of soluble Aβ.174 In contrast, genetic
ablation of A2A receptors in mice protects against AD phenotypes,
while optogenetic activation of this purinoceptor is sufficient to
induce memory deficits.175,176 These findings suggest that A1 and
A2A may exert opposite functions during AD progression. Epide-
miological studies indicate that caffeine, the non-selective antago-
nist of both A1 and A2A receptors, effectively improves cognitive
function and decreases the risk of AD.177,178 This observation implies
that the deleterious effects of A2A receptor may override the
protective effects of A1 receptor during AD progression. Moreover, it
has been reported that caffeine keeps blood–brain barrier intact,
thus preventing β-amyloid deposition in brain.179 Given that the
permeability of blood–brain barrier relies on multiple factors, the
protective effect of caffeine might be attributed to other potential
targets in addition to P1 receptors. Dysregulated ATP metabolism
due to impaired mitochondrial function, for example, is one of the
common characteristics in AD brain.180
Several studies demonstrated that P2X7 receptor inhibition
presents a neuroprotective effect in AD animal models.181,182 In rat
hippocampus, β-amyloid aggregates have been shown to co-
localise with P2X7 receptors.
183 This co-localisation coincides with
upregulated expression of P2X7 receptors, arguably linked to the
production of reactive oxygen species (ROS).184 Mechanistically,
P2X7 receptors promote β-amyloid deposition through α-secre-
tase. Amyloid precursor protein (APP) is cleaved by three family
members of secretase, namely α-, β-, and γ-secretase with
different cleavage sites. Cleavage by α-secretase produces soluble
fragment sAPP, which is harmless. Alternatively, β- and γ-secretase
generate toxic β-amyloid which contributes to formation of senile
plaques. Activation of P2X7 receptors was shown to inhibit the
activity of α-secretase through activating glycogen synthase
kinase 3 (GSK-3), leading to Aβ deposition in mice.185 However,
opposite findings have been also reported demonstrating that
P2X7 receptors activate α-secretase via modulation of MAPK
pathway to produce sAPP.186 These contradictory results indicate
that the role of P2X7 receptors in AD is yet to be characterised.
Depression is a neuropsychiatric disease characterised by
decreased self-esteem and interest loss, with a low quality of
personal life in aspects of sleeping, diet and general health.
Epidemiological studies indicate that moderate coffee intake
reduces the risk of depression, whereas excessive consumption
may worsen the situation.187,188 This observation highlights
possible involvement of A1 and A2A adenosine receptors.
Administration of ZM 241385, an inhibitor of A2A receptor,
decreases the immobility and isolation time in a rat depression
model, indicating that activation of A2A receptor contributes to
depressive behaviour.189 Consistently, rats overexpressing A2A
receptor demonstrate depressive phenotypes.190 In contrast,
stimulation of A1 receptor exhibits antidepressant effects.
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Activation of A1 receptors increases travel distance, whereas
knockout of A1 receptors leads to immobility and other depressive
behaviours in mice.191 Sleep deprivation, a widely used method to
temporally relief depression, acts through activating A1 recep-
tors.192 Consequently, moderate caffeine consumption predomi-
nantly inhibits A2A receptors to with anti-depressant effect,
whereas high dose of caffeine inhibits A1 receptors thus
worsening depressive symptoms. This hypothesis is supported
by the finding that antagonists for A2A, but not for A1 receptors,
potentiate effects of classic antidepressants. Two antidepressant
agents, agomelatine and tianeptine, were tested in combination
with selective inhibitor of A1 receptors (DPCPX) and A2A receptors
(DMPX). Such combination revealed that co-treatment with
DMPX, but not with DPCPX, increases the concentration of
agomelatine and tianeptine in the brain thus potentiating their
antidepressant effect.193 The P2 purinoceptors are also involved
in depression. Psychological stress induces the release of ATP,
activating P2X7 receptors thus leading to depressive behaviours
in mice; the anxiety behaviour can be reversed by administration
of P2X7 receptor antagonist.
194 Genetic deletion of P2X7 receptor
is anti-depressive in mice,
and increases the efficacy of antidepressant drugs.195 Single
nucleotide polymorphisms (SNPs) in A2A and P2X7 receptor genes
are linked to neuropsychiatric pathology. For example, the TT
genotype at rs2298383 SNP in A2A receptor predicts lower risk of
depression compared to the CC or CT genotypes.196 The rs2230912
polymorphism also causes a Gln460Arg mutation in P2X7 receptor,
which is associated with depression.197 These SNPs are believed to
serve as potential indicators for early risk assessment of depressive
disorders. Notably, several enzymes and metabolites of the
purinergic transmission are also potential biomarkers for depres-
sion. It has been found that increased activities of adenosine
Table 1. Several purinoceptors and their effects in neurotransmission in neurological diseases






































































































































Microglia Neuroprotection Pain disease 215
2-MeSATP 2-Methylthioadenosine-5′-O-triphosphate, αβ-meATP α,β-methyleneadenosine-5′-triphosphate, TNP-ATP 2′,3′-O-(2,4,6-Trinitrophenyl) adenosine
5′-triphosphate, PPADS pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid, BBG Brilliant Blue G, SGZ subgranular zone, SVZ subventricular zone, NMDAR
N-methyl-D-aspartate receptor, BDNF brain-derived neurotrophic factor
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deaminase (ADA) and xanthine oxidase (XO), as well as elevated
level of xanthine and hypoxanthine correlate with a higher risk of
depression.198 This evidence indicates that enzymes and metabo-
lites involved in purine metabolism, together with purinoceptors,
profoundly influence the pathophysiological function of nervous
system.
PURINERGIC TRANSMISSION IN MECHANOSENSORY
TRANSDUCTION AND PAIN
In 1977, the link between injection of ATP and other purines into
human skin blisters and initiation of pain was discovered.199 Since
then, a series of studies proved that activation of P2X receptors
leads to pain-related defensive behaviours in animals.200–202
Acupuncture, an ancient medicinal codex developed in China
over 4000 years, is used to relieve pain worldwide. Injection of A1
receptor agonist mimics the analgesic effect of acupuncture,
suggesting it works through activating A1 receptors.
203–205 To the
contrary, P2 receptors commonly potentiate pain signals. The P2X3
receptor is the best characterised pain-related P2 receptor; which
is predominantly expressed in small sensory neurones at dorsal
root ganglia (DRG). Elimination of P2X3 receptors by toxin leads to
a blunted response to acute pain in a rat model.206 In the context
of human diseases, P2X3 receptor is also associated with painful
diabetic neuropathy (PDN). Electroacupuncture decreases PKC-
mediated upregulation of P2X3 receptors in DRG, which attenu-
ates neuropathic pain and relieves PDN.207,208
Though positive effects have been observed in clinic, acupunc-
ture and electroacupuncture are invasive procedures which do not
fully satisfy the requirements of evidence-based medicine.
Therefore, selective agonists (mostly for P1 receptors) and
antagonists (mostly for P2 receptors) have been considered as
promising analgesic agents.93,209 For example, the agonist of A3
receptors IB-MECA has significant pain-relieving effects in a mouse
model.210 However, not all P1 receptor agonists with analgesic
properties in animal proved their worth in clinical trials (the WAG
994 being an example.211 As to antagonists of P2 receptors, A-
317491 a selective inhibitor of P2X3 and P2X2/3 receptors, is
capable of relieving acute and chronic nociception in rat
models,212,213 In addition, several P2 antagonists demonstrated
efficacy in clinical trials. The P2X7 receptor antagonist AZD9056
has been shown to relief pain without obvious side effects in a
phase II study.214 Similarly, antagonists for other P2 receptors
including P2X4 and P2Y12 receptors demonstrated analgesic
effects.215
PURINERGIC TRANSMISSION INTEGRATES IMMUNE SYSTEM
AND MODULATES INFLAMMATORY RESPONSES
Gout is classified as a rheumatic immune disease, and pain is
frequently companied by local inflammation.216 DNA, which is
composed of purines, activates innate immunity when being
translocated from nucleus or mitochondria into cytoplasm.217 This
suggests a critical role for purinergic transmission in the regulation
of immune system and inflammatory responses (Fig. 5). Purinergic
receptors are expressed in nearly all kinds of immune cells. For
instance, neutrophils express all four adenosine receptors and
several P2 receptors including P2X1, P2X7, P2Y2 and P2Y14
receptors.218 In addition, several ectoenzymes such as CD39 and
CD73 are expressed in immune cells; these enzymes regulate
Fig. 5 Purinergic signalling regulates immune and inflammatory responses. Besides necrotic cells, extracellular ATP can be released from
living cells through Panx1 channel. Extracellular ATP activates P2X7 receptors, which subsequently activate NLRP3 inflammasome to induce
the cleavage of pro-caspase-1. This effect leads to the maturation and release of caspase-1 thus initiating an immune or inflammatory
response. Alternatively, extracellular ATP is ready to be degraded into adenosine (ADO) by ectoenzymes such as CD39 and CD73. The
production of adenosine generally represses immune and inflammatory through binding with P1 receptors. In addition, P2X7 can be activated
by ADP-ribosylation using NAD+ as an ADP-ribose donor
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immune response through the production of adenosine from
ATP.219 In general, ATP serves as a danger signal that activates
immune cells, while adenosine attenuates inflammatory
responses.220 Conceptually, extracellular ATP activates P2 recep-
tors to initiate the immune response; subsequently ATP is
converted to adenosine by CD39, CD73 and other ectoenzymes,
leading to the activation of P1 receptors which contain
inflammation. This model is supported by a large body of
evidence. For example, CD39 and CD73 expressed in regulatory
T cells (Tregs) convert extracellular ATP to adenosine, which
suppresses the function of T effector cells.205 The recent finding
that CD39 knockout mice possess enhanced immunity due to
increased extracellular ATP and decreased adenosine, thus
producing more CD8+ T in their spleen to resist bacterial infection
further corroborates this model.221 Given the vital role of
extracellular ATP in the onset of immune response, a long-
standing question is that how ATP is released from the cells under
infectious lesions or tissue-damaging conditions. First, ATP derives
from necrotic cells.222 Second, ATP can be also released through
several types of channels, such as pannexin 1 (Panx1).223 In
contrast to necrosis, ATP released by Panx1 channel is regulated,
for certain stimuli such as hypoxia induces Panx1 to form an ATP
conduit, thereby accelerating ATP efflux.224
Functional P2X7 receptor is a trimeric complex with a variable
conformation switches between open (ATP-bound) and closed
states, which is one of the most intensively studied purinergic
receptors that shapes immune responses.225,226 Mounting evi-
dence suggests that P2X7 receptors control cytokine release and
immune cell activation, thus modifying immune and inflammatory
responses. For example, treatment with P2X7 receptor antagonist
Brilliant Blue G (BBG) markedly decreases the level of plasma TNF-
α in rats, thus suppressing the lipopolysaccharide (LPS)-induced
febrile response.227 Inhibition of P2X7 receptors by periodate-
oxidised ATP relieved allograft rejection in a cardiac transplanta-
tion mouse model; this relief being mediated by reduced T-cell
activation.228 Stimulation of P2X7 receptors activates NLRP3
inflammasome, thereby regulating immune and inflammatory
responses. Inhibition of P2X7 receptors prevents the activation of
NLRP3, leading to a decreased caspase-1 cleavage and reduced
sterile liver inflammation.229 Arguably there is a physical interac-
tion between P2X7 receptors and NLRP3, which explains a
molecular mechanism of P2X7 receptor-induced NLRP3 activa-
tion.230 Activated NLRP3 promotes the release of IL-1β through
cleaved caspase-1, thereby leading to inflammation.231 In P2X7
receptor knockout mice, the release of IL-1β from peritoneal
macrophages is largely blocked, indicating that P2X7 receptors are
required for IL-1β secretion.232 The P2X7 receptor is the most
potent activator of the NLRP3 inflammasome so far known, and
therefore a most potent stimulator of mature IL-1β release.
However, direct agonists of the NLRP3 inflammasome may trigger
IL-1β release in a P2X7 receptor-independent fashion.
233 Genetic
deletion of P2X7 receptor in mice did reduce, but never
completely abrogated the release of IL-1β.234 In addition to IL-
1β, another cytokine released by NLRP3 is IL-18, and involvement
of P2X7 receptor in IL-18 release has been documented.
235
Other purines that accumulate at inflammatory sites, i.e.
oxidised nicotinamide adenine dinucleotide (NAD+), may activate
the P2X7 receptor synergistically with ATP, at least in the
mouse.236 NAD+ provides an ADP-ribose that is covalently
transferred to protein substrates, which reaction is catalysed by
the ADP-ribosyltransferase (ART). This posttranslational modifica-
tion, known as ADP-ribosylation, occurs at the extracellular
domain of P2X7 receptor to initiate an inflammatory response.
237
Mounting evidence suggests that NAD+ not only provide
chemical group for ADP-ribosylation, but also mediate immune
and inflammatory responses, at least partially, independent of the
ADP-ribosylation. NAD+ shares considerable similarities with ATP
in terms of immunity modulation. Firstly, NAD+ and ATP are both
defined as danger signals.238–240 Secondly, both are released from
necrotic or damaged cells.241,242 Thirdly, both extracellular NAD+
and ATP can accumulate at high concentration at the injury
sites.243,244 Moreover, NAD+ itself is an agonist at P2Y11
receptor.245 This evidence indicates that NAD+ probably activates
immune responses similarly to ATP. Indeed, intravenous injection
of NAD+ significantly decreased the population of CD4+FoxP3+
Tregs, thereby promoting an antitumour response in vivo.237. On
the contrary, inhibition of NAD synthetase NAMPT has been
shown to decrease cytokine release, which can be used to
attenuate acute intestinal inflammation.246
PURINERGIC SIGNALLING REGULATES TUMOUR
DEVELOPMENT AND PROGRESSION
Inflammatory and immunosuppressive microenvironment is a
hallmark of cancer.247 Given the key roles of ATP and adenosine
as pro-inflammatory and anti-inflammatory agents, respectively,
this suggests a fundamental role of purinergic signalling in tumour
development and progression (Fig. 6). Tumour microenvironment
is rich in adenosine and ATP.100,248 It has been demonstrated that
ATP accumulates at tumour interstitium at hundreds of micromolar
while being nearly undetectable in the healthy samples.249 As
discussed in the previous section, ATP controls immune cells, and
accumulation of ATP triggers an antitumour immunity thus
inhibiting tumourigenesis.100 Several types of P2 receptors are
involved in the suppression of tumour growth, including P2X5,
P2X7, P2Y1, P2Y2 and P2Y11 receptors.
250,251 For example, P2X5
receptors contribute to the cytotoxic effects of T cells and
suppression of chronic myeloid leukaemia.252,253 In contrast,
knockout of P2X7 receptors decreases the population of CD8
+
cytotoxic T cells.254 Therefore, ATP enrichment in tumour micro-
environment seems to be an intrinsic antitumour mechanism
induced by immune system. However, P2 receptors are found not
only in immune cells, but also in cancer cells, making one
wondering why tumour cells express “suicidal” molecules.255 This
concern is even more pronounced due to the fact that extracellular
ATP not only leaks from necrotic cells, but derives from active
secretion associated with cancer cell metabolism.256,257 It appears
that the antitumour immunity is potentiated at a high level of ATP
(supplied pharmacologically), whereas a small increase of ATP
(released endogenously) promotes proliferation of cancer
cells.258,259 Indeed, overexpression or downregulation of P2X7
receptors has been shown to facilitate or suppress tumour growth,
respectively.260 Apart from the growth-promoting function, low
levels of ATP may also result in tumourigenesis through the release
of immunosuppressive cytokines, such as IL-10.261 This evidence
indicates that expression of certain P2 receptors provides
advantages for tumours but also imply a pharmacologic approach
towards cancer immunotherapy. According to this approach, ATP
infusion has been shown to relieve the loss of weight and restore
muscle strength in lung cancer patients.262,263
Adenosine similarly accumulates in tumour microenvironment
and affects the development and progression of cancer. Extracellular
adenosine largely derives from ATP breakdown, which is catalysed
by ectoenzymes including CD39 and CD73. All four subtypes of P1
receptors are expressed in tumour cells. For instance, A1 receptors is
overexpressed in renal cell carcinoma (RCC), and treatment with A1
receptors antagonist DPCPX inhibits RCC progression.264 Both A2A
and A2B receptors highly expressed in neuroendocrine tumours
promote proliferation of cancer cells.265 Activation of A3 receptors in
glioblastoma increases the migration and invasion of cancer cells
under hypoxia.266 As an immunosuppressive factor, adenosine
supports tumour growth, at least partially. through repressing the
antitumour immune responses. Genetic ablation or pharmacologic
inhibition of A2A receptors restores the antitumour activity of T cells,
suggesting potential strategy for the cancer immunotherapy.267,268
Given that ectoenzymes are largely responsible for the production
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of adenosine in tumour microenvironment, suppression of these
ectoenzymes (for example of CD73) has been shown to have
considerable effects to enhance antitumour immune responses, and
CD73-null mice are resistant to tumourigenesis.269,270 Adenosine
seems to regulate cancer development in a dose-dependent
manner in this resembling ATP. Endogenous adenosine converted
from extracellular ATP promotes the migration of breast cancer cells,
whereas exogenous adenosine or A3 receptors agonist IB-MECA
suppresses their mobility.271
Purinergic receptors modulate the activity of downstream
signalling cascades, thereby playing a role in cancer development
and progression. Adenylate cyclase and PLC are two major
effectors that couple with purinergic receptors and initiate
downstream signallings. Alteration of cAMP was found in
numerous malignancies.272 For instance, an increase in cAMP is
associated with hepatocellular carcinoma (HCC).273 In contrast, the
level of cAMP is decreased in lymphoma and ovarian cancer.274,275
Mechanistically, cAMP binds to the regulatory (inhibitory) subunits
of protein kinase A (PKA), leading to its activation. The
involvement of PKA in cancer has been extensively reviewed
elsewhere.276,277 Another downstream effector, PLC, catalyses the
production of diacyl glycerol (DAG) and InsP3 which both affect
tumourigenesis.278 These secondary messengers play central roles
in the signal transduction, linking purinergic signalling to other
pathways especially those involved in embryonic and tumour
development (i.e. Hippo, Wnt, Hedgehog, Notch and TGF-β).279–283
Genetic variations in the loci of purinergic receptors were
demonstrated to have a prognostic value for tumour chemother-
apy. Loss of P2X7 receptors allele promotes metastasis in
anthracycline-treated breast cancer patients due to a deficient
antitumour immunity compared with those patients harbouring a
wild-type P2X7 gene.
284
PREVENTION AND THERAPY OF PURINE-RELATED DISEASES
BY DIETARY AND HERBAL INTERVENTIONS
Hyperuricemia induced by dysregulation of purine metabolism is
associated with metabolic syndrome, which is also characterised
by other features including obesity, hyperglycaemia, hypertension,
hyperlipidemia and hyperinsulinemia. Similar to other metabolic
syndrome manifestations, purine-related diseases are closely
associated with the modern lifestyle.285 A 12-year perspective
study suggested that intake of meat and seafoods increase the risk
of gout to 1.41 and 1.51, respectively. In contrast, supplement with
dairy products decreases the risk to 0.56.286 Although high
abundance of purines in certain foods contributes to their
propensity to induce gout, intake of purine-rich vegetables is
not a risk factor.287 This difference might be attributed to the
different bioavailability of purine derivatives from an animal or
plant origin.288 Moreover, vegetables are beneficial for cardiovas-
cular diseases and obesity, which are linked to aberrant purine
metabolism.289,290 Therefore, vegetarian diet is beneficial regard-
less the purine content. Meat restriction calls for alternative
protein sources, with legumes and dairy products are ideal
choices. Inverse correlation between legume consumption and
hyperuricemia were observed in independent cohorts.291,292 Dairy
products have been found to reduce serum uric acid through the
uricosuric effects of casein and lactalbumin, two proteins derived
Fig. 6 Purinergic signalling involved in the initiation and progression of cancer. Tumour microenvironment is rich in purines, including
adenosine (AD) and other nucleotides. A panel of purinergic receptors are expressed in tumour cells to receive these extracellular purinergic
signals. Activation of P1 and P2Y receptors leads to an altered activity of adenylate cyclase or phospholipase C (PLC) by coupling different G
proteins (G), whereas activation of P2X receptors generates ion fluxes. These events change the level of several secondary messengers, such as
cAMP, Ca2+ and InsP3. InsP3 binds to the InsP3 receptors on endoplasmic reticulum (ER), leading to the release of Ca
2+ from ER. Thus,
numerous proteins are regulated by these secondary messengers, including PKA, PKC, GSK3β, CREB, androgen receptor (AR), MEK, p38, ERK
and ATF2. Among them are several transcription factors such as CREB, AR and ATF2, which induce a cancer-related transcription programme
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from the milk.293,294 Coffee is a beneficial beverage, being
associated with a lower risk of gout.295 Caffeine has been shown
to competitively inhibit xanthine oxidase, the enzyme producing
uric acid from hypoxanthine and xanthine.296 However, caffeine
alone failed to reduce the risk of gout, suggesting that other
components of coffee contribute to its beneficial effect.295
Dietary interventions are consistent with a theory of food
homology according to traditional Chinese medicine (TCM), which
describes that most foods hold therapeutic potential so that there
is no absolute segregation between foods and drugs. In addition
to physical methods such as acupuncture and cupping, TCM is
mainly referred to herbal medicine that exhibits multi-targets
effects. For instance, cortex phellodendri amurensis is one of the
commonly used TCM for the treatment of gout.297 This effect
might be attributed to its three components, berberine, phello-
dendrine and magnoflorine, all of which are capable of regulating
inflammatory or antioxidant responses.298–300 Other TCM used for
the treatment of gout include Radix Achyranthis Bidentatae,
Rhizoma Atractylodis Lancea, Rhizoma Smilacis Glabrae, Semen
Coicis Albais and Largehead Atractylodis Rhizome, with active
ingredients such as β-ecdysterone, β-eudesmol, hinesol, atractylon
and astilbin that exhibit anti-inflammatory, antioxidant or
analgesic effects (Fig. 7).301 Importantly, in the clinic practice,
different kinds of herbs are combined as complex formulae to
minimise side effect and enhanced therapeutic outcome. For
example, Erding granule (EDG) composed of Viola yedoensis
Makino, Lobelia chinensi Lour, Isatis indigotica Fort and other
components has been shown to reduce uric acid and suppress
inflammation possibly via downregulating the expression of
GLUT9 and URAT1 in a mouse model, suggesting this formula
can be a potential agent for the treatment of hyperuricemia.302
It is worth mentioning that dietary and herbal interventions
are useful for disease prevention or treatment at early stages.
When diseases reach advanced stages, however, evidence-based
medicine with specific drug target remains an optimal choice
(Fig. 7). Hitherto, a number of drugs targeting purine metabolism
or purinergic signalling have been developed. The US FDA
database, contains several approved purinergic signalling target-
related drugs, which include ADO injection [P1 receptor agonist
used for the treatment of paroxysmal supraventricular tachycardia
(PSVT) including that associated with accessory bypass tracts
(Wolff–Parkinson–White syndrome)]; Cafcit (Caffeine citrate) injec-
tion (P1 receptor antagonist for the treatment of apnoea of
prematurity); Lexiscan (regadenoson) injection (A2A receptor
agonist, used as a pharmacologic stress agent in radionuclide
myocardial perfusion imaging, a test that detects and charac-
terises coronary artery disease, in patients unable to undergo
adequate exercise stress); Nourianz (Istradefylline) tablets (A2A
Fig. 7 Traditional Chinese medicine and evidence-based medicine with therapeutic potential for purine-related diseases. Several TCM have
been found to show considerable effect in the treatment of gout, including Cortex Phellodendri Amurensis, Radix Achyranthis Bidentatae,
Rhizoma Atractylodis Lancea, Rhizoma Smilacis Glabrae, Semen Coicis Albais, Viola yedoensis Makino, Lobelia chinensi Lour, Isatis indigotica
Fortune and so on. These TCM share similarities in terms of their components, which usually contain antioxidant and anti-inflammatory
materials such as berberine, phellodendrine and magnoflorine. Combinational use of TCM as a formula might improve therapeutic efficacy
and minimised adverse effect. In addition, FDA-approved drugs including istradefylline, dipyridamole, suramin, clopidogrel, prasugrel,
cangrelor, ticagrelor, etc. are also therapeutic options targeting purine metabolism or purinoceptors
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receptor antagonist used as an add-on treatment to levodopa/
carbidopa in adult patients with Parkinson’s disease experiencing
“off” episodes); Brilinta (ticagrelor) tablets (P2Y12 receptor
antagonist, treatment for acute coronary syndrome, coronary
artery disease, cardiovascular risk reduction, ischaemic stroke, and
prophylaxis); Effient (Prasugrel) tablets (P2Y12 receptor antagonist,
oral antiplatelet agent for the treatment of patients with acute
coronary syndrome who are managed with percutaneous
coronary intervention including coronary stenting); Kengreal
(Cangrelor) injection (P2Y12 receptor antagonist, intravenous
P2Y12 platelet inhibitor indicated for use in patients undergoing
percutaneous coronary intervention to reduce the risk of
periprocedural thrombotic events); Plavix (Clopidogrel bisulfate)
tablets (P2Y12 receptor antagonist, indicated for the reduction of
atherothrombotic events such as recent myocardial infarction,
recent stroke, or established peripheral arterial disease, and acute
coronary syndrome); and dipyridamole tablets (inhibiting the
uptake of adenosine into platelets, endothelial cells and erythro-
cytes in vitro and in vivo, used as an adjunct to coumarin
anticoagulants in the prevention of postoperative thromboem-
bolic complications of cardiac valve replacement). In addition, a
variety of drugs have been studied and applied in clinic for the
treatment of different diseases although they have not got
approval from FDA. For example, Diquafosol (tradename Diquas) is
a P2Y2 receptor agonist that has been approved for the treatment
of dry eye disease in Japan in 2010 and it is available for dry eye
treatment in Japan, South Korea, Thailand, Vietnam, and China.
Topical instillation of 3% diquafosol ophthalmic solution increased
lipid layer thickness within 60 min in normal human eyes
regardless of age303 and the recent real-world study showed that
diquafosol 3.0% ophthalmic solution was well tolerated and
effective in the long-term treatment (12 months) of dry eye.304
The Phase 3 trial for Denufosol (inhaled P2Y2 agonists for the
treatment of cystic fibrosis) is in the progress. The Phase 2 clinical
trial of AZD9056 (P2X7 receptor antagonist) demonstrated
statistically significant decrease in Crohn’s Disease Activity Index
from baseline in Crohn’s patients receiving 200 mg AZD9056 (UID
for 4 weeks). Another P2X7 antagonist JNJ-54175446 is an orally
bioavailable, central nervous system-penetrating; it is currently in
Phase 2 clinical trial for the treatment of major depressive disorder
(clinicaltrials.gov,NCT04116606). AF-219/gefapixant, a P2X3 recep-
tor antagonist has been through a randomised, double-blind,
placebo-controlled phase 2 study for the treatment of the
refractory chronic cough305 and a randomised, double-blind,
controlled, parallel-group, phase 2b trial for the treatment of
refractory or unexplained chronic cough.306 All of these drugs
should be strongly recommended as new therapies with widened
clinic applications.
CONCLUDING REMARKS
Apart from serving as building blocks and energy source, purines
regulate numerous cellular processes by initiating purinergic
signalling. Purine metabolism regulated by purinosome deter-
mines the availability of purines, which act as endogenous
ligands for a panel of purinergic receptors. Activation of
purinergic receptors controls the production of various secondary
messengers including cAMP, DAG, IP3 and Ca
2+, thus leading to
physiological consequences in normal conditions. In contrast,
unhealthy diet, genetic variation or other pathological events
disturbs purine metabolism, resulting neurodegeneration, gout,
pain, inflammation and cancer. In addition to these disorders,
purinergic signalling is related with many other diseases
including cardiac, gastrointestinal, muscular, reproductive dis-
orders and so on. Due to the extreme complexity of human body,
we did not cover all these aspects, while we focused on
representative examples.
As the novel drug target, purinergic signalling has a promising
future in the development of new drugs or new indications due to
current success in ADO, A1, A2a, and P2Y12 receptors. However,
any of the four main purines, ATP, ADP, AMP, and ADO in the
purinergic system, any of the three key enzymes, CD39, E-NPP,
and CD73, and any of the 19 purinergic receptors, four P1
receptors (A1, A2A, A2B, A3), seven P2X (P2X1–7), and eight P2Y
(P2Y1,2,4,6,11–14) need more attention in the future. In particular, the
following therapies may come true in the near future: ATP for
depression, AD; ADO for sleep disorders; CD73 for cancer or
inflammation; A1 receptor for pain and sleep disorders; A2A
receptor for AD and PD; P2X1 receptor for bladder disorder and
hypertension; P2X3 receptor for cough and hypertension; P2X7
receptor for cytokine release syndrome, inflammatory disease,
brain disorders, and cancer; P2Y2 receptor for dry eye; P2Y12
receptor for pain and inflammation beyond current indications
approved by FDA.
Though remarkable progress has been made in this field,
several details remain to be elucidated for an in-depth under-
stating towards purinergic signalling. For instance, how does each
component of purinosome is well organised to form together and
translocated to mitochondria? How to target a specific purinergic
receptor without affecting other family members in the same
subgroup? How to minimise potential side effects when targeting
purinergic receptors due to multiple secondary messengers are
simultaneously affected? These concerns need to be addressed
before purine-based therapeutic strategies can be broadly applied
for the treatment of relevant human diseases.307–309
We miss the creator of Purinergic Signalling310,311 Prof. Geoffrey
Burnstock and we are very grateful for his great contributions to
the discovery and characterisation of this novel molecular target
for the development of promising drugs to treat human disease.
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